Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2024-10-04 00:00:00 ET · period of report 2024-10-02 · accession 0000950170-24-112980 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-04 | 2024-10-02 | NTLA | Dube Michael P | VP, CAO | S - Sale | $19.01 | -2,012 | 47.0K | -4% | -$38.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-02 | S | D | 2,012 | $19.01 | 47,012 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.01, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 2, 2024 at each separate price. |